Enveric Biosciences, Inc. (ENVB) - 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. Enveric Biosciences, Inc. is a biotechnology company developing small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders. The company's lead candidate, EB-003, is a non-hallucinogenic compound targeting 5-HT 2A and 5-HT 1B receptors, currently in preclinical development. The company operates as a single segment and has not yet generated revenue.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(4,661,206) | $(4,704,147) |
| Operating Expenses | $4,660,611 | $4,706,582 |
| Cash and Cash Equivalents (End of Period) | $8,296,296 | $2,849,816 |
| Working Capital | $7,931,850 | N/A |
| Accumulated Deficit | $(119,507,698) | $(110,778,652) |
| Net Cash Used in Operating Activities | $(4,701,378) | $(4,281,724) |
| Net Cash Provided by Financing Activities | $8,348,207 | $4,898,010 |
Material Changes vs. Prior Period
- Financing Activity: The company significantly increased its cash position through equity financing. In the six months ended June 30, 2026, the company raised approximately $5.0 million in a private placement (April 2026) and $1.3 million via its At-The-Market (ATM) facility. Additionally, warrant exercises generated $1.5 million in proceeds.
- Operating Expenses: Total operating expenses decreased slightly by approximately 1% year-over-year ($4.66M vs $4.71M). This was driven by a 15% decrease in Research and Development (R&D) expenses, offset by a 12% increase in General and Administrative (G&A) expenses due to higher salaries and franchise taxes.
- Capital Structure: Following a 1-for-12 reverse stock split in October 2025, the company issued significant shares in 2026. Outstanding common stock increased from 1,061,533 shares at year-end 2025 to 3,935,884 shares as of June 30, 2026.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for one year from the filing date. Current cash resources ($8.3M) are insufficient to fund operations for the next 12 months. The company anticipates needing additional capital through equity or debt financing.
- Development Progress: EB-003 has completed short-term toxicology studies and initiated GLP-compliant genotoxicity studies in June 2026 to support a future Investigational New Drug (IND) filing. The company also unveiled the EVM401 Series to broaden its pipeline.
- Internal Controls: The company disclosed that its disclosure controls and procedures were not effective as of June 30, 2026, due to material weaknesses related to limited personnel, inadequate segregation of duties, and insufficient oversight.
- Listing Risk: The company faces potential delisting risks under new Nasdaq Market Value of Listed Securities (MVLS) requirements, which mandate a minimum market value of $5 million. While currently compliant, the company notes its MVLS has been near this threshold.
Investor Verification Checklist
- Verify the sufficiency of the $8.3M cash balance against the projected burn rate and the timeline for the next financing round.
- Confirm the status of the remediation plan for the material weaknesses in internal controls over financial reporting.
- Monitor the company's Market Value of Listed Securities (MVLS) to ensure continued compliance with Nasdaq listing standards.
- Review the terms of the April 2026 private placement warrants (Series I and J) and their potential dilution impact upon exercise.
- Track the progress of EB-003's IND-enabling studies and the timeline for the anticipated IND filing.